TissueGene

Starting in 1997, the founders of TissueGene sought to uncover different surgical and gene-based therapeutics for a variety of arthritic conditions. The diligence soon paid off in the form of the first successful animal model for cartilage repair. Subsequently, in the middle of 1999, TissueGene, Inc was incorporated in the United States. TissueGene's initial findings resulted in the focused development of a proprietary cell mediated genetic technology capable of treating and regenerating damaged tendons, ligaments, cartilage and bones. The company began using a form of cell mediated gene therapy to deliver a regenerative protein to damaged tissue, which catalyzes rapid and permanent repair of the injured site without the need for surgery

Contact Details: 209 Perry Parkway, Suite 13 Gaithersburg Maryland 20877 United States of America Tel: (301) 921-6000 Fax: (301) 921-6011 Email: contact@tissuegene.com WWW: www.tissuegene.com/

Loading...

Recent Publications by TissueGene:
Irradiated human chondrocytes expressing bone morphogenetic protein 2 promote healing of osteoporotic bone fracture in rats. Bone morphogenetic protein 2 (BMP2) was selected as a transgene to...	4th March, 2009	TissueGene, Inc., Rockville, Maryland, USA.	Tissue Eng Part A. 2009 Oct;15(10):2853-63. DOI Direct Link
Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. One of the most important factors in the production of cartilage is...	24th June, 2005	TissueGene,	Tissue Eng. 2005 Jan-Feb;11(1-2):310-8. DOI Direct Link
Retroviral gene therapy: safety issues and possible solutions. The recent incidents of leukemia development in X-SCID patients after a...	25th May, 2005	TissueGene Inc., Gaithersburg, MD 20877, USA.	Curr Gene Ther. 2005 Feb;5(1):25-35.

Press Releases on TissueGene:
TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee	2nd March, 2009	TissueGene, Inc.	ROCKVILLE, Md., March 2 /PRNewswire/ -- TissueGene, Inc. announced today that its South Korean licensing partner Kolon Life Science, Inc. (KLS) has received regulatory allowance from the Korea Food

TissueGene Patents:
US Patent No.	Title
7431922	Bioadhesive directed somatic cell therapy
7338655	Gene therapy using TGF-.beta.
7282200	Mixed-cell gene therapy
7005127	Mixed-cell gene therapy
6797703	Gene therapy using TGF-.beta.
→View more TissueGene patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 348 times since April 2007, the link to the organisation's website has been followed 67 times

Recent Search Terms used to find this page: tissuegene | .

Search for more companies in Gaithersburg

Search for more companies in Maryland

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for TissueGene